This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Agency for Science, Technology and Research, National University of Singapore, Prilenia Neurotherapeutics Ltd.. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 1,564 
3 out of 857 
2 out of 25 Years Active: 2022-2026
Title: Mahmoud Abdulhossein Pouladi: Innovator in Fragile X Syndrome Treatment
Introduction
Mahmoud Abdulhossein Pouladi is a notable inventor based in Singapore, recognized for his contributions to the field of neurotherapeutics. He has made significant strides in developing treatments for fragile X syndrome, a genetic condition that affects cognitive development.
Latest Patents
Pouladi holds a patent for the "Use of pridopidine for the treatment of fragile X syndrome." This invention provides a method for treating individuals afflicted with fragile X syndrome or related disorders. The method involves periodically administering a pharmaceutical composition containing an effective amount of pridopidine to the subject. This innovative approach aims to improve the quality of life for those affected by this condition.
Career Highlights
Throughout his career, Pouladi has worked with prominent organizations, including Prilenia Neurotherapeutics Ltd. and the National University of Singapore. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
One of his notable collaborators is Michael Hayden, with whom he has worked on various projects related to neurotherapeutics. Their partnership has been instrumental in advancing the understanding and treatment of fragile X syndrome.
Conclusion
Mahmoud Abdulhossein Pouladi's innovative work in the treatment of fragile X syndrome highlights his commitment to improving patient outcomes through scientific research and collaboration. His contributions to the field are invaluable and continue to inspire future advancements in neurotherapeutics.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile